{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:04:43Z","timestamp":1780351483722,"version":"3.54.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.7759\/cureus.110072","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:49:57Z","timestamp":1780350597000},"source":"Crossref","is-referenced-by-count":0,"title":["Intrahepatic Cholangiocarcinoma: The Weight of History"],"prefix":"10.7759","author":[{"given":"Telma","family":"Costa Cabral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rita","family":"Ambr\u00f3sio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Miguel","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ism\u00e9nia de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"P\u00eago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava N","year":"2014","unstructured":"Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014, 383:2168-79. 10.1016\/S0140-6736(13)61903-0","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001672","article-title":"Anatomic subsets of cholangiocarcinoma: more different than alike","author":"Dong Y","year":"2026","unstructured":"Dong Y, Stumpf HE, Smoot RL, Starlinger PP, Yarchoan MM, Gores GJ, Ilyas SI. Anatomic subsets of cholangiocarcinoma: more different than alike. Hepatology. 2026, 10.1097\/HEP.0000000000001672","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus CL","year":"2023","unstructured":"Bowlus CL, Arriv\u00e9 L, Bergquist A, et al.. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023, 77:659-702. 10.1002\/hep.32771","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle JW","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021, 397:428-44. 10.1016\/S0140-6736(21)00153-7","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Ilyas SI","year":"2018","unstructured":"Ilyas SI, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018, 15:95-111. 10.1038\/nrclinonc.2017.157","journal-title":"Nat Rev Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24351","article-title":"Risk factors for cholangiocarcinoma","volume":"54","author":"Tyson GL","year":"2011","unstructured":"Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011, 54:173-84. 10.1002\/hep.24351","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.09.007","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"72","author":"Clements O","year":"2020","unstructured":"Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020, 72:95-103. 10.1016\/j.jhep.2019.09.007","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30030199","article-title":"Bone metastases from intrahepatic cholangiocarcinoma confer worse prognosis","volume":"30","author":"Garajov\u00e1 I","year":"2023","unstructured":"Garajov\u00e1 I, Gelsomino F, Salati M, Leonardi F, De Lorenzo S, Granito A, Tovoli F. Bone metastases from intrahepatic cholangiocarcinoma confer worse prognosis. Curr Oncol. 2023, 30:2613-24. 10.3390\/curroncol30030199","journal-title":"Curr Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE- 966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley RK","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al.. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE- 966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023, 401:1853-65. 10.1016\/S0140-6736(23)00727-4","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales JM","year":"2020","unstructured":"Banales JM, Marin JJ, Lamarca A, et al.. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020, 17:557-88. 10.1038\/s41575-020-0310-z","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca A","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, et al.. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021, 22:690-701. 10.1016\/S1470-2045(21)00027-9","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh DY","year":"2025","unstructured":"Oh DY, He AR, Qin S, et al.. Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study. J Hepatol. 2025, 83:1092-101. 10.1016\/j.jhep.2025.05.003","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21759","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and\u00a0future\u00a0therapeutic landscape for clinicians","volume":"73","author":"Moris D","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and\u00a0future\u00a0therapeutic landscape for clinicians. CA Cancer J Clin. 2023, 73:198-222. 10.3322\/caac.21759","journal-title":"CA Cancer J Clin"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/469731-intrahepatic-cholangiocarcinoma-the-weight-of-history","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:49:58Z","timestamp":1780350598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/469731-intrahepatic-cholangiocarcinoma-the-weight-of-history"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.110072","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}